Navigation Links
Proteolix Initiates Phase 1b Clinical Trial of Carfilzomib in a Combination Regimen for Patients With Relapsed Multiple Myeloma
Date:7/10/2008

Provides Update on Carfilzomib Development Program in Multiple Myeloma

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Proteolix, Inc. today announced that patient dosing has commenced in a Phase 1b clinical trial to evaluate the safety and efficacy of Proteolix's lead anti-cancer agent, carfilzomib (PR-171), in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells. In single agent Phase 1 studies carfilzomib has demonstrated encouraging anti-tumor activity and has been generally well tolerated.

The Phase 1b clinical trial is designed to evaluate safety and to establish a maximum-tolerated dose of carfilzomib in combination with lenalidomide and dexamethasone on a twenty-eight day treatment cycle. Lenalidomide in combination with dexamethasone is indicated for use in patients with multiple myeloma who have had at least one prior therapy. Patients will be divided into four cohorts and will receive escalating doses of carfilzomib and lenalidomide, combined with a set dose of dexamethasone. A secondary endpoint for the trial is overall response rate at four months.

"Carfilzomib has been generally well-tolerated in patients and we believe that the product's selectivity and potency provide a solid rationale for use in combination with existing treatment protocols," said Lori Kunkel, M.D., Proteolix's Chief Medical Officer. "Initiating our first combination trial of carfilzomib complements our multi-pronged strategy to thoroughly explore carfilzomib's potential in the treatment of patients with multiple myeloma for whom treatment options may be limited."

Carfilzomib Clinical Program in Multiple Myeloma

In addition to the Phase 1b clinical trial announced today, Proteolix is currently evaluating carfilzomib as a single agent for the treatment of multiple myeloma in two Phase 2 clinical trials.

A Pha
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
3. Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients With Relapsed Solid Tumors
4. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
7. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
8. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
9. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
10. Nuvelo Re-Initiates SONOMA-3 Trial of Alfimeprase in Patients With Catheter Occlusion
11. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., BATESVILLE, Ind. and MCDONOUGH, Ga., Nov. 9 /PR...d Encompass Group today announced the formation of...istribution of a comprehensive range of surface re...arate from a bed frame and as replacements for sur...end of their useful life. Hill-Rom, a global lead...
(Date:11/9/2009)..., ,, PRINCETON, N.J., Nov. 9 /PRNewswire...nnounces management will present at the Sixth Annu...he conference will be held at the St Regis Hotel i...efer Price, Pharmasset,s President and Chief Execu...any on Wednesday, November 18, 2009 at 3:45 PM (ET...
(Date:11/9/2009)..., HOUSTON, Nov. 9 Patent attorne...tipkala, Ph.D., J. D., will showcase Stipkala LLC ...3, 2009, which will be held at the Institute of Mo...cience Conference provides a platform for cutting-...ties to investors, and will feature keynote addres...
Breaking Medicine Technology:Hill-Rom and Encompass Group Form Joint Venture 2Hill-Rom and Encompass Group Form Joint Venture 3Hill-Rom and Encompass Group Form Joint Venture 4Hill-Rom and Encompass Group Form Joint Venture 5Pharmasset to Present at Lazard Capital Markets Healthcare Conference 2Pharmasset to Present at Lazard Capital Markets Healthcare Conference 3Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 1Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 2Feel Fun Fit 26 Fabulous 21 At the 2009 Womens Health Conference 52117 3Our brain looks at eyes first to identify a face 9280 1Our brain looks at eyes first to identify a face 9280 2Our brain looks at eyes first to identify a face 9280 3Scholarships Available for PA Breast Cancer Coalition Annual Conference 52115 1Scholarships Available for PA Breast Cancer Coalition Annual Conference 52115 2
...,Contributing Editor , ,Positive patient ide...editing bodies for the past few years. Until rece...are were beyond the reach of the average hospital ...ith devices that can be integrated into a facility...ter for small facilities, while others are best fo...
...vard Medical School ,Contributing Editor , ,...per year, breast cancer undoubtedly qualifies as o...ntly, efforts to develop early detection methods a...ress. This is particularly true at the molecular ...e translated into new diagnostic tests and targete...
Other Medicine Technology:Managing Preanalytical Processes for Patient Safety 2Managing Preanalytical Processes for Patient Safety 3Managing Preanalytical Processes for Patient Safety 4Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 2Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy 3
(Date:11/9/2009)...GTON, Nov. 9 The Churchill Centr...d For Leadership to J.W. "Bill" Marriott for his l...progressive free market practices and fostering an... Marriott will receive his award at a ceremony and...D.C. Four Seasons Hotel. ,, "This is a testame...
(Date:11/9/2009)...e left atrial enlargement, study finds , ... major risk factor for left atrial enlargement, wh...oke and death, a new study shows. , Atrial fibr... irregular heart rhythm or heartbeat). , Resea...25 to 74, in Germany who were followed for 10 year...
(Date:11/9/2009)...due to fact that both eye conditions are age-relat...HealthDay News) -- Cataract surgery doesn,t appear...egeneration (AMD), according to a new study that c...sion loss worsens the other. , "Because both co...s with cataract also have AMD," wrote Li Ming Dong...
(Date:11/9/2009)...are increases with longer doctor visits, researche...s) -- Family doctors are now taking more time cons... and improving the quality of visits, a new study ...r primary care physicians during office visits in ...erall they seemed to receive better care," said Dr...
(Date:11/9/2009)... Course, to be Offered in April 2010,... , Cambridge, MA (Vocus) ...ans for Human Rights (PHR) first inspected a suspe... he realized he would need a team of experts to he...he site properly was a key first step in securing ...
Breaking Medicine News(10 mins):Health News:J.W. 'Bill' Marriott to Receive Churchill Centre Award For Leadership 2Health News:Cataract Surgery Doesn't Worsen Macular Degeneration: Study 2Health News:Doctors Spending More Time Now With Patients 2Health News:Doctors Spending More Time Now With Patients 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4
...n worms are shedding new light on the hormone,s ro...lthDay News) -- Scientists have gained new insight...the groundwork for an anti-aging treatment. , The...s whose insulin levels were adjusted lived a week ...
...nati, OH March 20, 2008 In workplaces where nurs...es, the health of nurses suffers, and the retentio...le published in the Journal of Obstetric, Gynecolo... environment. , More than half of nurses surveye...
...gton, DC, March 20, 2008 -- The Association for Pr...(APIC) today announced a detailed strategy to comb.... The initiative begins with the first national pr...rrhea and more serious intestinal conditions such ...
...as appeared among Hispanic Enterprise,s best compa...nce 2005, COLUMBUS, Ga., March 20 Aflac Incorpor... supplier diversity list by Hispanic,Enterprise ma...ase and are,committed to the economic prosperity i...
... March 20, 2008 A bodysuit that heats or cools a...ye movements, is providing multiple sclerosis rese...ew tool to study the mysterious link between body ...ho reported in 1889 that some people have temporar...
...PARK, Kan., March 20 A recent outbreak of,Eastern...rong reminder to,horse owners throughout the count...r dangerous mosquito-borne diseases. To ensure you...at protects,against West Nile virus, EEE and Weste...
Other Medicine News:Health News:Tweaking Insulin Might Help Fight Aging 2Health News:APIC launches first national C. difficile prevalence study 2Health News:Aflac Named Among the 50 Best Companies for Supplier Diversity 2Health News:Eye test peers into heat-related multiple sclerosis symptoms 2Health News:Fort Dodge's 'Mosquito Shot' Offers Convenient Protection Against Dangerous Mosquito-Borne Illnesses 2
Thyroglobulin Autoantibody - ELISA
Coat-a-Count Estradiol RIA
... the quantitative determination of Estradiol (E2) ...(E2) is a C18 steroid hormone with a phenolic A ri...f 272.4. It is the most potent natural Estrogen, ...ller amounts by the adrenal cortex, and the male t...
AxSYM Troponin-I ADV
Medicine Products: